Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRINT: Warfarin Monitoring Interval
NCT00356759Phase 2Completed
- Sponsor
- Hamilton Health Sciences
- Start
- Dec 2006
- Primary completion
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of warfarin in Atrial fibrillation (AFib), heart valve disease (VHD) and venous thrombosis (2 arms), sponsored by Hamilton Health Sciences. Primary endpoint: Time in Therapeutic Range at 12 months. Started Dec 2006; status: completed.
02
Drugs
warfarin
03
Conditions
Atrial fibrillation (AFib)heart valve disease (VHD)venous thrombosis
Beyond the preview
Go deeper on NCT00356759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00356759.